Cassava Sciences Inc (SAVA) USD0.001
Sell:$1.65Buy:$1.69
$0.07
(4.40%)
- This stock can be held in a
Stocks and Shares ISA$0.07
(4.40%)$0.07
(4.40%)Company Information
About this company
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Key people
Key facts
- EPICSAVA
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS14817C1071
- Market cap$70.53m
- Employees30
- Shares in issue48.31m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.